Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod Phase 2/3 in Moderate-to-Severe Atopic Dermatitis
NCT05732454Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of etrasimod in atopic dermatitis (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Investigator's Global Assessment Response at 16 weeks, Number of Participants With Treatment Emergent Adverse Events at 56 weeks and 5 more. Started Jan 2023; status: terminated.
02
Drugs
etrasimod
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05732454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732454.